Studie

Prospective pilot trial to assess a multimodal molecular targeted therapy in children, adolescent and young adults with relapsed or refractory high-grade pineoblastoma

Erkrankungsgruppe:

ZNS und Gehirntumore

Organsystem:

Gehirn, Zentrales Nervensystem

Stadium:

Rückfall, Therapierefraktär

Standort:

Dortmund, Homburg/ Saar

EudraCT:

2015-004304-27

Prüfplan-Code:

RIST-rPB-2015-P

Phase:

II/III

Prüfsubstanz:

Sprycel, Temomedac, Rapamune, Irinomedac

Sponsor:

Universitätsklinikum Regensburg